Companies · Other Health Care

Sera Prognostics, Inc.

SALT LAKE CITY · Other Health Care

Diligence memoA one-page analyst read on Sera Prognostics, Inc. — recommendation, valuation, rhythm, risks.
$217.7M
Total raised · real
9
Rounds
0.6×
Latest step-up
Top 2%
Sector rank · raised
Series D+
Latest stage · inferred · Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Sera Prognostics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.61× the median modeled value of Series D+ Other Health Care companies in 2019–2021 (26 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Sera Prognostics, Inc. is one of 5376 Other Health Care companies tracked from SALT LAKE CITY. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2021-02-23
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries A · 2011-11-08 Raised $10M (real) Modeled valuation $206M (est)Series A2011Series A · 2011-11-08 Raised $10M (real) Modeled valuation $206M (est)Series A2011Series A · 2013-09-20 Raised $4.5M (real) Modeled valuation $91M (est)Series A2013Seed · 2013-09-20 Raised $1.3M (real) Modeled valuation $31M (est)Seed2013Series A · 2014-05-30 Raised $9.2M (real) Modeled valuation $185M (est)Series A2014Series A · 2014-11-07 Raised $5.0M (real) Modeled valuation $101M (est)Series A2014Series B · 2017-01-09 Raised $23M (real) Modeled valuation $504M (est)Series B2017Series B · 2018-11-30 Raised $7.6M (real) Modeled valuation $168M (est)Series B2018Series B · 2019-02-26 Raised $6.4M (real) Modeled valuation $142M (est)Series B2019Series B · 2019-07-31 Raised $26M (real) Modeled valuation $571M (est)Series B2019Series C · 2019-07-31 Raised $52M (real) Modeled valuation $1.2B (est)Series C2019Series D+ · 2021-02-23 Raised $100M (real) Modeled valuation $2.0B (est)Series D+2021Series C · 2021-02-23 Raised $62M (real) Modeled valuation $1.2B (est)Series C2021Cumulative $316M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$10.2M · 2011
Series A extension$10.2M · 2011
Series A extension$4.5M · 2013
Bridge · Series A-stage$1.3M · 2013smaller follow-on
Series A extension$9.2M · 2014
Series A extension$5.0M · 2014
Series B$22.7M · 2017
Series B extension$7.6M · 2018
Series B extension$6.4M · 2019
Series B extension$25.8M · 2019
Series C$51.8M · 2019
Series D+$100.3M · 2021
Bridge · Series D+-stage$61.5M · 2021smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 83%.

Modeled valuation trajectory
$2.0B
Base estimate est.
$534.3M
Conservative case
$4.1B
Upside case
$835.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $206.4M · 2011-11-082011Series A · modeled $206.4M · 2011-11-08Series A · modeled $90.8M · 2013-09-20Seed · modeled $31.0M · 2013-09-20Series A · modeled $184.8M · 2014-05-30Series A · modeled $100.9M · 2014-11-07Series B · modeled $503.7M · 2017-01-09Series B · modeled $167.8M · 2018-11-30Series B · modeled $141.8M · 2019-02-26Series B · modeled $570.9M · 2019-07-31Series C · modeled $1.2B · 2019-07-31Series D+ · modeled $2.0B · 2021-02-23Series C · modeled $1.2B · 2021-02-232021
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
80%
Survival probability
64% low · 88% high
1.23×/yr
Annual markup
1.38×/yr upside case
5.3 yr
Elapsed time used
5.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
9 mo
Avg between rounds
$23.4M/yr
Capital velocity
14.6 yr
On record since
2011
First round
13
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 90× above median
This company$217.7M
Sector median$2.4M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.5× of median
This company$61.5M
Sector median$123.0M
Modeled value — vs sector median (estimate, all stages) 91× above median
This company$2.0B
Sector median$22.1M

Raised more than 99% of sector peers (real $). Modeled value above 98% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #19 of 26.

This companyCohort peer
$1.0B$10.0B$100.0M$1.0BCapital raised (log)ZAHN Parent, LLC · Series D+ Raised $379.9M · modeled $8.7B (est)Covetrus, Inc. · Series D+ Raised $361.1M · modeled $8.3B (est)EQH Parent, LLC · Series D+ Raised $334.2M · modeled $6.7B (est)SonerMed, LLC · Series D+ Raised $300.0M · modeled $6.7B (est)Fs Usme Lp · Series D+ Raised $282.0M · modeled $6.0B (est)Medable Inc. · Series D+ Raised $501.0M · modeled $5.4B (est)Cedar Cares, Inc. · Series D+ Raised $569.4M · modeled $5.1B (est)Inotiv, Inc. · Series D+ Raised $280.1M · modeled $4.8B (est)Orca BioSystems Inc · Series D+ Raised $192.0M · modeled $4.4B (est)Magnolia (MH) Holdings, L.P. · Series D+ Raised $259.8M · modeled $4.4B (est)eHealth, Inc. · Series D+ Raised $225.0M · modeled $4.4B (est)ECG Europe, Inc. · Series D+ Raised $200.0M · modeled $3.6B (est)Sera Prognostics, Inc. (this company) Raised $217.7M · modeled $2.0B (est)Sera Prognostics, Inc.
CompanyStageRaised · realValue · estvs peer med.
ZAHN Parent, LLCSeries D+$379.9M$8.7B2.64×
Covetrus, Inc.Series D+$361.1M$8.3B2.51×
EQH Parent, LLCSeries D+$334.2M$6.7B2.04×
SonerMed, LLCSeries D+$300.0M$6.7B2.02×
Fs Usme LpSeries D+$282.0M$6.0B1.80×
Medable Inc.Series D+$501.0M$5.4B1.63×
Cedar Cares, Inc.Series D+$569.4M$5.1B1.54×
Inotiv, Inc.Series D+$280.1M$4.8B1.45×
Orca BioSystems IncSeries D+$192.0M$4.4B1.33×
Magnolia (MH) Holdings, L.P.Series D+$259.8M$4.4B1.33×
eHealth, Inc.Series D+$225.0M$4.4B1.32×
ECG Europe, Inc.Series D+$200.0M$3.6B1.09×
Sera Prognostics, Inc. this companySeries D+$217.7M$2.0B0.61×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$10.2M2011-11-08$46.5M$206.4M85%
Series A$10.2M2011-11-08$46.5M$206.4M85%
Series A$4.5M2013-09-20$20.5M$90.8M85%
Seed$1.3M2013-09-20$6.3M$31.0M85%
Series A$9.2M2014-05-30$41.6M$184.8M85%
Series A$5.0M2014-11-07$22.7M$100.9M85%
Series B$22.7M2017-01-09$126.3M$503.7M90%
Series B$7.6M2018-11-30$42.1M$167.8M90%
Series B$6.4M2019-02-26$35.6M$141.8M90%
Series B$25.8M2019-07-31$143.2M$570.9M90%
Series C$51.8M2019-07-31$345.1M$1.2B90%
Series D+$100.3M2021-02-23$835.8M$2.0B90%
Series C$61.5M2021-02-23$410.0M$1.2B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$10.2M2011-11-08
    • First recorded raise — entered as Series A.
    • 15 investors on this round.
  2. Series A$10.2M2011-11-08
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 15 investors on this round.
  3. Series A$4.5M2013-09-20
    • Raised again after 22 mo — slower than the ~14 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
    • 11 investors on this round.
  4. Seed$1.3M2013-09-20
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.6× smaller than the prior — bridge or down round.
    • 11 investors on this round.
  5. Series A$9.2M2014-05-30
    • Raised 8 mo later, in step with the ~14 mo sector norm.
    • Round 7.3× larger than the prior — scaling up.
    • 15 investors on this round.
  6. Series A$5.0M2014-11-07
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 15 investors on this round.
  7. Series B$22.7M2017-01-09
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 4.5× larger than the prior — scaling up.
    • 5 investors on this round.
  8. Series B$7.6M2018-11-30
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 3.0× smaller than the prior — bridge or down round.
    • 12 investors on this round.
  9. Series B$6.4M2019-02-26
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
  10. Series B$25.8M2019-07-31
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round 4.0× larger than the prior — scaling up.
    • 18 investors on this round.
  11. Series C$51.8M2019-07-31
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
    • 28 investors on this round.
  12. Series D+$100.3M2021-02-23
    • Raised 19 mo later, in step with the ~14 mo sector norm.
    • Round 1.9× larger than the prior — scaling up.
    • 16 investors on this round.
  13. Series C$61.5M2021-02-23
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.6× smaller than the prior — bridge or down round.
    • 6 investors on this round.
Intelligence
2021 ~Q4
Modeled next raise · ~9mo cadence
$61.5M
Modeled next size est.range $61.5M$98.4M
0.6×
Last step-up
$23.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gregory C. Critchfield2 other2011-11
Mansoor Raza Mirza2 other2017-01
Dennis B. Farrar1 other2011-11
Marcus M. Wilson1 other2021-02
Andrew A. Sauter2011-11
Arnold B. Oronsky, Ph.D.2017-01
Charles D. Kennedy2019-07
Charles M. Kennedy2021-02
Douglas B. Fisher2014-11
Douglas M. Fisher2011-11
Elizabeth B. Canis2021-02
Jay C. Moyes2021-02
Joseph M. Siletto2021-02
Joshua B. Phillips2017-01
Joshua L. Phillips2014-11
Joshua M. Phillips2011-11
Kim B. Kamdar2014-11
Kim M. Kamdar2011-11
Mansoor M. Mirza2021-02
Mark J. Ostrowski2011-11
Michael M. Minahan2021-02
Michael Raza Minahan2017-01
Richard L. Novak2011-11
Ryan M. Trimble2011-11
Registry & provenance

Sera Prognostics, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1534969
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Zimmer Biomet Holdings, Inc.Other Health CareSeries D+$216.1M$2.9Bsame sector · same stage
Glooko, Inc.Other Health CareSeries D+$221.0M$1.2Bsame sector · same stage
Evolent Health LLCOther Health CareSeries D+$221.3M$2.3Bsame sector · same stage
Main Street Rural, Inc.Other Health CareSeries D+$211.2M$2.4Bsame sector · same stage
Cortica Inc.Other Health CareSeries D+$210.9M$757.4Msame sector · same stage
Richmond Buyer L.P.Other Health CareSeries D+$232.6M$2.2Bsame sector · same stage
ECG Europe, Inc.Other Health CareSeries D+$200.0M$3.6Bsame sector · same stage
VeraDermics, IncOther Health CareSeries D+$239.3M$1.0Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
General Prognostics, Inc.Other Health CarePre-Seed$849K89%
PrognomIQ, Inc.Other Health CareSeries B$49.0M89%
Protean Biodiagnostics Inc.Other Health CareSeries A$35.4M83%
ImmuneTarget, Inc.Other Health CarePre-Seed$18.7M83%
NOWDiagnostics, Inc.Other Health CareSeries B$420.4M82%
Quality Biomedical, Inc.Other Health CareSeries A$100.9M82%
ImmunSYS, Inc.Other Health CarePre-Seed$8.7M82%
Prognos Health Inc.HealthtechSeries B$235.0M81%
Frequently asked
How much funding has Sera Prognostics, Inc. raised?
Sera Prognostics, Inc. has raised approximately $217.7M in disclosed capital across 9 recorded financing rounds, aggregated from public filings.
What is Sera Prognostics, Inc.'s estimated valuation?
Provath's modeled valuation for Sera Prognostics, Inc. is approximately $2.0B (modeled range $534.3M–$4.1B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Sera Prognostics, Inc. at?
Sera Prognostics, Inc.'s latest modeled financing stage is Series D+. Its most recent recorded round closed around Tue Feb 23.
What does Sera Prognostics, Inc. do and where is it based?
Sera Prognostics, Inc. operates in the Other Health Care sector, based in SALT LAKE CITY.
Explore related

See where Sera Prognostics, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Sera Prognostics, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.